<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00022724</url>
  </required_header>
  <id_info>
    <org_study_id>NABTC-0101</org_study_id>
    <secondary_id>CDR0000068848</secondary_id>
    <nct_id>NCT00022724</nct_id>
  </id_info>
  <brief_title>CCI-779 in Treating Patients With Malignant Glioma</brief_title>
  <official_title>Phase I/II Trial Of CCI-779 In Patients With Malignant Glioma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins</source>
  <brief_summary>
    <textblock>
      RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so&#xD;
      they stop growing or die.&#xD;
&#xD;
      PURPOSE: Phase I/II trial to study the effectiveness of CCI-779 in treating patients who have&#xD;
      malignant glioma.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
        -  Determine the maximum tolerated dose of CCI-779 in patients with malignant glioma.&#xD;
&#xD;
        -  Determine the safety profile of this drug in these patients.&#xD;
&#xD;
        -  Determine the pharmacokinetics of this drug in these patients.&#xD;
&#xD;
        -  Determine the efficacy of this drug, in terms of survival and objective response, in&#xD;
           these patients.&#xD;
&#xD;
      OUTLINE: This is a dose-escalation study. Patients in phase II are stratified according to&#xD;
      use of enzyme-inducing antiepileptic drugs (EIAEDs) (yes vs no) and disease type&#xD;
      (glioblastoma multiforme with stable neuro-imaging after radiotherapy vs recurrent malignant&#xD;
      glioma). Patients in phase I must be currently receiving EIAEDs.&#xD;
&#xD;
        -  Phase I: Patients receive CCI-779 IV over 30 minutes once weekly. Treatment repeats&#xD;
           every 4 weeks in the absence of disease progression or unacceptable toxicity.&#xD;
&#xD;
      Cohorts of 3-6 patients receive escalating doses of CCI-779 until the maximum tolerated dose&#xD;
      (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6&#xD;
      patients experience dose-limiting toxicity.&#xD;
&#xD;
        -  Phase II: Patients receive CCI-779 as in Phase I. Patients who are candidates for&#xD;
           surgical resection of recurrent disease receive CCI-779 IV over 30 minutes 2 hours prior&#xD;
           to surgery and then once weekly, as above, once recovered from surgery.&#xD;
&#xD;
      Patients are followed for survival.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 36 patients will be accrued for phase I of this study within 12&#xD;
      months. A total of 87 patients will be accrued for phase II of this study within 12 months.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">August 27, 2001</start_date>
  <completion_date type="Actual">December 15, 2007</completion_date>
  <primary_completion_date type="Actual">May 4, 2006</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <enrollment type="Anticipated">49</enrollment>
  <condition>Brain and Central Nervous System Tumors</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>temsirolimus</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically confirmed intracranial malignant glioma&#xD;
&#xD;
               -  Glioblastoma multiforme&#xD;
&#xD;
               -  Anaplastic astrocytoma&#xD;
&#xD;
               -  Anaplastic oligodendroglioma&#xD;
&#xD;
               -  Anaplastic mixed oligoastrocytoma&#xD;
&#xD;
               -  Malignant astrocytoma not otherwise specified&#xD;
&#xD;
          -  Initial diagnosis of low-grade allowed, if subsequently progressed&#xD;
&#xD;
          -  Recurrent disease must have documented progression by MRI or CT scan&#xD;
&#xD;
          -  Progressive disease must have failed prior radiotherapy&#xD;
&#xD;
          -  Recent resection of recurrent or progressive tumor allowed provided all of the&#xD;
             following are met:&#xD;
&#xD;
               -  Recovered from surgery&#xD;
&#xD;
               -  CT scan or MRI performed no more than 96 hours postoperatively OR at 4-6 weeks&#xD;
                  postoperatively&#xD;
&#xD;
               -  Concurrent steroid dosage must be stable&#xD;
&#xD;
          -  Confirmation of true progressive disease (by PET, thallium scan, MR spectroscopy, or&#xD;
             surgical documentation) required after prior interstitial brachytherapy or&#xD;
             stereotactic radiosurgery&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Age:&#xD;
&#xD;
          -  18 and over&#xD;
&#xD;
        Performance status:&#xD;
&#xD;
          -  Karnofsky 60-100%&#xD;
&#xD;
        Life expectancy:&#xD;
&#xD;
          -  More than 8 weeks&#xD;
&#xD;
        Hematopoietic:&#xD;
&#xD;
          -  WBC at least 3,000/mm3&#xD;
&#xD;
          -  Absolute neutrophil count at least 2,000/mm3&#xD;
&#xD;
          -  Platelet count at least 120,000/mm3&#xD;
&#xD;
          -  Hemoglobin at least 10 g/dL (transfusion allowed)&#xD;
&#xD;
        Hepatic:&#xD;
&#xD;
          -  Bilirubin less than 1.5 times upper limit of normal (ULN)&#xD;
&#xD;
          -  SGOT less than 1.5 times ULN&#xD;
&#xD;
          -  Cholesterol less than 350 mg/dL&#xD;
&#xD;
          -  Triglycerides less than 400 mg/dL&#xD;
&#xD;
        Renal:&#xD;
&#xD;
          -  Creatinine less than 1.5 mg/dL&#xD;
&#xD;
          -  Creatinine clearance at least 60 mL/min&#xD;
&#xD;
        Other:&#xD;
&#xD;
          -  No active infection&#xD;
&#xD;
          -  No other malignancy within the past 3 years except nonmelanoma skin cancer or&#xD;
             carcinoma in situ of the cervix&#xD;
&#xD;
          -  No significant medical illness that would preclude study&#xD;
&#xD;
          -  No disease that would obscure toxicity or dangerously alter drug metabolism&#xD;
&#xD;
          -  No history of allergic reactions attributed to compounds of similar chemical or&#xD;
             biologic composition to CCI-779 or allergy to or inability to receive antihistamines&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use effective contraception during and for 12 weeks after study&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Biologic therapy:&#xD;
&#xD;
          -  At least 1 week since prior interferon&#xD;
&#xD;
        Chemotherapy:&#xD;
&#xD;
          -  At least 2 weeks since prior vincristine&#xD;
&#xD;
          -  At least 3 weeks since prior procarbazine&#xD;
&#xD;
          -  At least 6 weeks since prior nitrosoureas&#xD;
&#xD;
          -  Phase I:&#xD;
&#xD;
               -  2 prior chemotherapy regimens allowed&#xD;
&#xD;
               -  1 prior adjuvant regimen and 1 prior regimen for recurrent or progressive disease&#xD;
                  OR&#xD;
&#xD;
               -  2 prior regimens for progressive tumor&#xD;
&#xD;
          -  Phase II:&#xD;
&#xD;
               -  No more than 1 prior chemotherapy regimen for recurrent malignant glioma&#xD;
&#xD;
               -  No prior chemotherapy allowed for stable glioblastoma multiforme&#xD;
&#xD;
        Endocrine therapy:&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  At least 1 week since prior tamoxifen&#xD;
&#xD;
        Radiotherapy:&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  At least 4 weeks since prior radiotherapy for progressive disease&#xD;
&#xD;
          -  No more than 1 month since prior radiotherapy for nonprogressive glioblastoma&#xD;
             multiforme&#xD;
&#xD;
        Surgery:&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
        Other:&#xD;
&#xD;
          -  Recovered from prior therapy&#xD;
&#xD;
          -  At least 1 week since prior noncytotoxic agents&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>120 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Susan M. Chang, MD</last_name>
    <role>Study Chair</role>
    <affiliation>University of California, San Francisco</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Jonsson Comprehensive Cancer Center at UCLA</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UCSF Comprehensive Cancer Center</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94143</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Warren Grant Magnuson Clinical Center - NCI Clinical Studies Support</name>
      <address>
        <city>Bethesda</city>
        <state>Maryland</state>
        <zip>20892-1182</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dana-Farber/Harvard Cancer Center at Dana Farber Cancer Institute</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Michigan Comprehensive Cancer Center</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48109-0942</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan-Kettering Cancer Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10021</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hillman Cancer Center at University of Pittsburgh Cancer Institute</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15232</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>M.D. Anderson Cancer Center at University of Texas</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030-4009</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Texas Health Science Center at San Antonio</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78284-6220</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Wisconsin Comprehensive Cancer Center</name>
      <address>
        <city>Madison</city>
        <state>Wisconsin</state>
        <zip>53792</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Kuhn JG, Chang SM, Wen PY, Cloughesy TF, Greenberg H, Schiff D, Conrad C, Fink KL, Robins HI, Mehta M, DeAngelis L, Raizer J, Hess K, Lamborn KR, Dancey J, Prados MD; North American Brain Tumor Consortium and the National Cancer Institute. Pharmacokinetic and tumor distribution characteristics of temsirolimus in patients with recurrent malignant glioma. Clin Cancer Res. 2007 Dec 15;13(24):7401-6.</citation>
    <PMID>18094423</PMID>
  </results_reference>
  <results_reference>
    <citation>Chang SM, Wen P, Cloughesy T, Greenberg H, Schiff D, Conrad C, Fink K, Robins HI, De Angelis L, Raizer J, Hess K, Aldape K, Lamborn KR, Kuhn J, Dancey J, Prados MD; North American Brain Tumor Consortium and the National Cancer Institute. Phase II study of CCI-779 in patients with recurrent glioblastoma multiforme. Invest New Drugs. 2005 Aug;23(4):357-61.</citation>
    <PMID>16012795</PMID>
  </results_reference>
  <results_reference>
    <citation>Chang SM, Kuhn J, Wen P, Greenberg H, Schiff D, Conrad C, Fink K, Robins HI, Cloughesy T, De Angelis L, Razier J, Hess K, Dancey J, Prados MD; North American Brain Tumor Consortium And The National Cancer Institute. Phase I/pharmacokinetic study of CCI-779 in patients with recurrent malignant glioma on enzyme-inducing antiepileptic drugs. Invest New Drugs. 2004 Nov;22(4):427-35.</citation>
    <PMID>15292713</PMID>
  </results_reference>
  <verification_date>June 2018</verification_date>
  <study_first_submitted>August 10, 2001</study_first_submitted>
  <study_first_submitted_qc>January 26, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 27, 2003</study_first_posted>
  <last_update_submitted>June 22, 2018</last_update_submitted>
  <last_update_submitted_qc>June 22, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">June 26, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>recurrent adult brain tumor</keyword>
  <keyword>adult glioblastoma</keyword>
  <keyword>adult anaplastic astrocytoma</keyword>
  <keyword>adult anaplastic oligodendroglioma</keyword>
  <keyword>adult mixed glioma</keyword>
  <keyword>adult giant cell glioblastoma</keyword>
  <keyword>adult gliosarcoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glioma</mesh_term>
    <mesh_term>Nervous System Neoplasms</mesh_term>
    <mesh_term>Central Nervous System Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sirolimus</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

